Literature DB >> 10024956

Early histologic appearance of human patellar tendon autografts used for anterior cruciate ligament reconstruction.

B T Rougraff1, K D Shelbourne.   

Abstract

Nine patients underwent second-look arthroscopy and biopsy between 3 and 8 weeks after anterior cruciate ligament (ACL) reconstruction using autogenous patellar tendon. All nine biopsies were taken from the central region of the graft. Every biopsy revealed viable cells in two different patterns. As early as 3 weeks after ACL reconstruction, there were areas that were very similar to patellar tendon control specimens with low nuclear counts, mature collagen, and elongated, metabolically quiescent nuclear morphology. Other areas were hypercellular and associated intimately with neovascular invasion. Vascularity of the grafts was present as early as 3 weeks after reconstruction and increased in prevalence over the next 5 weeks. All specimens had areas of acellularity and degeneration. From these data, the authors conclude that the transplantation of nonvascularized, autogenous patellar tendon is characterized by early viability of the graft both from original fibroblasts and by new cells that arise from neovascularity that is present as early as 3 weeks after ACL reconstruction.

Entities:  

Mesh:

Year:  1999        PMID: 10024956     DOI: 10.1007/s001670050113

Source DB:  PubMed          Journal:  Knee Surg Sports Traumatol Arthrosc        ISSN: 0942-2056            Impact factor:   4.342


  18 in total

1.  Second-look arthroscopic findings of 208 patients after ACL reconstruction.

Authors:  Jin Hwan Ahn; Jae Chul Yoo; Hyoung Seop Yang; Jae Hoon Kim; Joon Ho Wang
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2006-10-07       Impact factor: 4.342

Review 2.  "Biological failure" of the anterior cruciate ligament graft.

Authors:  J Ménétrey; V B Duthon; T Laumonier; D Fritschy
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-01-09       Impact factor: 4.342

Review 3.  Graft healing in anterior cruciate ligament reconstruction.

Authors:  Max Ekdahl; James H-C Wang; Mario Ronga; Freddie H Fu
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-07-17       Impact factor: 4.342

4.  Graft size after anterior cruciate ligament reconstruction.

Authors:  Daniel Hensler; Motoko Miyawaki; Kenneth D Illingworth; Carola F van Eck; Freddie H Fu
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-09-01       Impact factor: 4.342

Review 5.  Graft remodeling and ligamentization after cruciate ligament reconstruction.

Authors:  S U Scheffler; F N Unterhauser; A Weiler
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-05-31       Impact factor: 4.342

6.  PATIENT-SPECIFIC AND SURGERY-SPECIFIC FACTORS THAT AFFECT RETURN TO SPORT AFTER ACL RECONSTRUCTION.

Authors:  Rick Joreitz; Andrew Lynch; Stephen Rabuck; Brittany Lynch; Sarah Davin; James Irrgang
Journal:  Int J Sports Phys Ther       Date:  2016-04

7.  Evidence for plical support of the patella.

Authors:  Robert M Geraghty; Michelle Spear
Journal:  J Anat       Date:  2017-07-18       Impact factor: 2.610

8.  Evaluation with contrast-enhanced magnetic resonance imaging of the anterior cruciate ligament graft during its healing process: a two-year prospective study.

Authors:  Aikaterini Ntoulia; Frederica Papadopoulou; Franceska Zampeli; Stavros Ristanis; Maria Argyropoulou; Anastasios Georgoulis
Journal:  Skeletal Radiol       Date:  2012-12-11       Impact factor: 2.199

9.  Cells from a GDF5 origin produce zonal tendon-to-bone attachments following anterior cruciate ligament reconstruction.

Authors:  Yusuke Hagiwara; Felix Dyrna; Andrew F Kuntz; Douglas J Adams; Nathaniel A Dyment
Journal:  Ann N Y Acad Sci       Date:  2019-10-09       Impact factor: 5.691

10.  Collagen-platelet composite enhances biomechanical and histologic healing of the porcine anterior cruciate ligament.

Authors:  Shilpa M Joshi; Ashley N Mastrangelo; Elise M Magarian; Braden C Fleming; Martha M Murray
Journal:  Am J Sports Med       Date:  2009-12       Impact factor: 6.202

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.